For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Selling, general and administrative | 12,208 | |||
| Research and development | 4,094 | |||
| Change in fair value of contingent consideration | -3,499 | |||
| Total operating costs and expenses | 12,803 | |||
| (loss) income from operations | -12,803 | |||
| Change in fair value of convertible notes | -22,911 | |||
| Change in fair value of warrants | -84,934 | |||
| Loss on issuance of warrants | -75,644 | |||
| Loss on derivative liability | 13,088 | |||
| Other income, net | 290 | |||
| Total other loss, net | -26,419 | |||
| (loss) income before taxes | -39,222 | |||
| Net (loss) income | -39,222 | |||
| Basic EPS | -3.95 | |||
| Diluted EPS | -3.95 | |||
| Basic Average Shares | 9,921,587 | |||
| Diluted Average Shares | 9,921,587 | |||
AEON Biopharma, Inc. (AEON)
AEON Biopharma, Inc. (AEON)